We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis.
The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over 36 months of treatment: PURE Study‘ was presented at the AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
Questions
- What have we learned about the clinical utility of secukinumab in the treatment of psoriasis and what questions remain unanswered? (0:20)
- Could you tell us a little about the rationale, objectives, design and inclusion criteria of the PURE registry? (1:19)
- What was the impact of secukinumab in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months in patients with plaque psoriasis? (3:33)
- What other outcomes were reported in this study? (5:21)
- What future studies are planned within the PURE registry? (7:48)
Disclosures: KAP has served as a consultant, speaker, clinical researcher, scientific officer, steering committee member, or advisor for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dice Pharmacueticals, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck- Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, UCB and Xencor.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the AAD VMX 2021.
